Core Insights - Shuttle Pharmaceuticals Holdings, Inc. is focused on improving outcomes for cancer patients treated with radiation therapy, with significant developments in their clinical trials and diagnostics [1][2][3] Group 1: Clinical Developments - The company has commenced a Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with over one-third of the initial randomized enrollment completed [2][4] - As of the latest update, 16 out of 40 patients have been enrolled in the trial, with 8 patients completing all seven cycles [4] Group 2: Diagnostic Advancements - Shuttle Diagnostics, a subsidiary of the company, is advancing its diagnostic capabilities, including a PC-Rad test for localized prostate cancer and a PSMA-B ligand for metastatic prostate cancer [2][4] - A sponsored research agreement with the University of California, San Francisco (UCSF) has been established to further develop a theranostic molecule targeting prostate-specific membrane antigen (PSMA) [4] Group 3: Corporate Developments - The company has launched a new corporate website to highlight its dual approach to cancer therapeutics and diagnostics [4] - Significant investments have been made into the business, including a recent financing transaction where the CEO contributed $237,500 [4]
Shuttle Pharma Provides Corporate Update and Reports 2024 Results